Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis

Arthritis Care and Research

Volumn 62, Issue 2, 2010, Pages 204-212

  Albers, H M ^a   Brinkman, D M C ^a   Kamphuis, S S M ^b   Van Suijlekom Smit, L W A ^b   Van Rossum, M A J ^c   Hoppenreijs, E P A H ^d   Girschick, H J ^e   Wouters, C ^f   Saurenmann, R K ^g   Houwing Duistermaat, J J ^a   Huizinga, T W J ^a   Schilham, M W ^a   Ten Cate, R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID;

ARTICLE; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; INFANT; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PROGNOSIS; REMISSION; SCHOOL CHILD;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 75749134134     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20069     Document Type: Article

References (17)

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31: 390-2.
2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
3. Adib N, Silman A, Thomson W. Outcome following onset of juvenile idiopathic inflammatory arthritis. I. Frequency of different outcomes. Rheumatology (Oxford) 2005;44:995-1001.
4. Adib N, Silman A, Thomson W. Outcome following onset of juvenile idiopathic inflammatory arthritis. II. Predictors of outcome in juvenile arthritis. Rheumatology (Oxford) 2005; 44:1002-7.
5. Ravelli A, Martini A. Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol 2003;21(5 Suppl 31): S89-93.
6. Ravelli A, Martini A. Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 2006;24(6 Suppl 43):S105-10.
7. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
8. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554-62.
9. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29:1989-99.
10. Flato B, Aasland A, Vinje O, Forre O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol 1998;25:366-75.
11. Oen K, Reed M, Malleson PN, Cabral DA, Petty RE, Rosenberg AM, et al. Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. J Rheumatol 2003;30:832-40.
12. Magni-Manzoni S, Ruperto N, Pistorio A, Sala E, Solari N, Palmisani E, et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1120-7.
13. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Reed M, et al. Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations. J Rheumatol 2003;30:585-93.
14. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch National Register. Ann Rheum Dis 2009;68:635- 41.
15. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al, for the FIN-RACo Trial Group. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FINRACo study. Arthritis Rheum 2004;50:2072-81.
16. Sokka T, Makinen H, Puolakka K, Mottonen T, Hannonen P. Remission as the treatment goal: the FIN-RACo trial. Clin Exp Rheumatol 2006;24 Suppl 43:S74-6.
17. Makinen H, Kautiainen H, Hannonen P, Mottonen T, Leirisalo-Repo M, Laasonen L, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007;34:316-21.